© 2017

Mechanisms of Molecular Carcinogenesis – Volume 2

  • Johannes Haybaeck

Table of contents

  1. Front Matter
    Pages i-viii
  2. Iva Brčić, Marija Balić
    Pages 1-22
  3. Birgit Aigner, Franz Legat, Wolfgang Weger
    Pages 23-39
  4. Maria A. Smolle, Johannes Haybaeck
    Pages 41-63
  5. Iva Brčić, Catarina Callé, Cord Langner
    Pages 65-82
  6. V. Taucher, Johannes Haybaeck
    Pages 83-118
  7. Nicole Golob-Schwarzl, Sonja Kessler, Johannes Haybaeck
    Pages 119-140
  8. Nadine Gantenbein, Johannes Haybaeck
    Pages 141-146
  9. Alexander JA Deutsch, Katharina Troppan, Karoline Fechter, Peter Neumeister
    Pages 147-169
  10. Maria A. Smolle, Johannes Haybaeck, Martin Pichler
    Pages 171-189
  11. Rita Seeböck, Johannes Haybaeck
    Pages 191-205
  12. Amin El-Heliebi, Ellen Heitzer, Thomas Kroneis, Shukun Chen, Christoph Haudum, Julia Fuchs
    Pages 233-261
  13. Peter J. Schüffler, Qing Zhong, Peter J. Wild, Thomas J. Fuchs
    Pages 263-279
  14. Alessandra Silvestri, Dirk Schumacher, Maxine Silvestrov, Reinhold Schäfer, Christoph Reinhard, Jens Hoffmann et al.
    Pages 281-313
  15. Myria Galazi, Gregory Weitsman, James Monypenny, Oana Coban, Hanna Milewicz, Valenti Gomez et al.
    Pages 315-358
  16. Hans Lehrach, Thomas Kessler, Lesley Ogilvie, Moritz Schütte, Christoph Wierling
    Pages 359-374

About this book


Together with Volume 1, this book provides an inclusive overview of the molecular and cellular mechanisms of carcinogenesis and offers comprehensive insights into related clinical and therapeutic aspects. 
This second volume complements the first by presenting and concisely explaining the carcinogenesis of various tumor entities such as non-melanoma skin cancers, bone and soft tissue tumors, pancreatic cancers, hepatocellular cancer and neuroendocrine tumors. As in volume one, each chapter illuminates the similarities and dissimilarities of changed signaling pathways in the different organ systems and depicts potential therapeutic strategies. The focus of volume two lies on the presentation of modern molecular biological techniques for diagnosis, as well as strategies for biomarker identification and validation. Furthermore, it discusses potential therapeutic targets and individualized treatment strategies, offering a valuable resource for all basic scientists and medical researchers interested in translational cancer research.


cancer biomarkers mechanism of carcinogenesis molecular cancer diagnostics molecular cancer profile targeted cancer therapy translational cancer research imaging novel diagnostic tools

Editors and affiliations

  • Johannes Haybaeck
    • 1
  1. 1.Department of Pathology, Medical FacultyOtto von Guericke University MagdeburgMagdeburgGermany

About the editors

Prof. Johannes Haybaeck is a professor of Pathology at the Department of Pathology, Medical Faculty of the University of Magdeburg, Germany. He is a board certified pathologist and neuropathologist who is also specialized in molecular biology. Prof. Haybaeck received his first degree in Medicine at Innsbruck University, Austria, prior to further studies at the University of Zurich, Innsbruck and Salzburg. He received his PhD degree at the Mathematical and Natural Science Faculty of the University of Zurich. Since 2010, he has led his own research group and has been a consultant for pathology and neuropathology.  In 2011, he was nominated as Vice Chair, and since 2014, he has held the title of Chairman of the Department of Neuropathology at the Medical University of Graz, Austria. He was elected as Founding Coordinator for Cancer Research, Education and Training of the Comprehensive Cancer Center (CCC) Graz for two periods. In 2016, he was nominated as Full Professor and Head of the Department of Pathology at Magdeburg University Hospital in Germany. In his capacity as a surgical pathologist and neuropathologist, he is confronted with diagnostic questions on a daily basis. Accordingly, his research focuses on the cellular and molecular mechanisms driving carcinogenesis. Together with his coworkers in Magdeburg and Graz, he is constantly engaged in the development of novel models mimicking the human situation in order to establish prognostic and predictive biomarkers and to generate novel therapies.

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods